MedTrace Logo

Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation

NCT04838704 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2025-06-04

No results posted yet for this study

Summary

Low Dose Ruxolitinib with Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor plus Methotrexate and Mycophenolate mofetil as Graft Versus Host Disease prophylaxis for HLA-haploidentical hematopoietic stem cell transplantation in low-dose antithymocyte globulin (ATG) system.

Conditions

Interventions

DRUG

Ruxolitinib+Calcineurin inhibitor+Methotrexate

low-dose ruxolitinib combine with calcineurin inhibitor and short course of methotrexate.

DRUG

Calcineurin Inhibitor+Methotrexate+Mycophenolate mofetil

calcineurin inhibitor and short course of methotrexate and mycophenolate mofetil

Sponsors & Collaborators

  • The Children's Hospital of Zhejiang University School of Medicine

    collaborator OTHER

  • Yinzhou Hospital Affiliated to Medical School of Ningbo University

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04838704 on ClinicalTrials.gov